Holen Sie sich die Stockscreener-App
52.62
3.09%
-1.68
Schlusskurs vom Vortag:
$54.30
Offen:
$53.85
24-Stunden-Volumen:
852.44K
Relative Volume:
1.68
Marktkapitalisierung:
$3.34B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-145.21M
KGV:
-22.88
EPS:
-2.3
Netto-Cashflow:
$-140.12M
1W Leistung:
-11.47%
1M Leistung:
-4.05%
6M Leistung:
+33.86%
1J Leistung:
+3.10%
1-Tages-Spanne:
$52.45
$54.97
1-Wochen-Bereich:
$52.45
$61.17
52-Wochen-Spanne:
$31.42
$61.87
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Vergleichen Sie MLTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
52.62 | 3.44B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
MoonLake Immunotherapeutics $MLTX Shares Sold by Fred Alger Management LLC - MarketBeat
Psoriasis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma - Barchart.com
Zimmer Partners LP Makes New Investment in MoonLake Immunotherapeutics $MLTX - MarketBeat
Biotech UCB’s Big Rally Has a Lot Riding on Rival’s Trial Result - SWI swissinfo.ch
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6.9%Here's Why - MarketBeat
Octagon Capital Advisors LP Buys Shares of 296,000 MoonLake Immunotherapeutics $MLTX - MarketBeat
Alliancebernstein L.P. Sells 56,514 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
Granahan Investment Management LLC Has $5.56 Million Stock Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
Cubist Systematic Strategies LLC Takes Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX) - Yahoo Finance
FY2025 EPS Estimates for MLTX Decreased by Cantor Fitzgerald - MarketBeat
ADAR1 Capital Management LLC Sells 12,000 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Hits New 1-Year HighStill a Buy? - MarketBeat
Russell Investments Group Ltd. Sells 50,430 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
Vestal Point Capital LP Acquires Shares of 200,000 MoonLake Immunotherapeutics $MLTX - MarketBeat
What’s the analyst consensus on MoonLake ImmunotherapeuticsTrade Analysis Summary & Fast Entry High Yield Tips - خودرو بانک
Forecasting MoonLake Immunotherapeutics price range with options dataRecession Risk & Daily Growth Stock Investment Tips - Newser
Using economic indicators to assess MoonLake Immunotherapeutics potentialJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
How to use a screener to detect MoonLake Immunotherapeutics breakoutsWatch List & Trade Opportunity Analysis - Newser
How to track smart money flows in MoonLake ImmunotherapeuticsPortfolio Gains Report & Verified High Yield Trade Plans - Newser
What institutional flow reveals about MoonLake ImmunotherapeuticsInflation Watch & Weekly Momentum Stock Picks - Newser
What MACD and RSI say about MoonLake ImmunotherapeuticsWeekly Stock Summary & Safe Entry Zone Identification - Newser
Can technical indicators confirm MoonLake Immunotherapeutics’s reversalJuly 2025 News Drivers & Consistent Growth Stock Picks - Newser
Paradigm Biocapital Advisors LP Decreases Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
What are MoonLake Immunotherapeutics’s growth leversWeekly Stock Recap & Safe Entry Zone Identification - خودرو بانک
Can MoonLake Immunotherapeutics keep up with sector leaders2025 Market Outlook & Community Shared Stock Ideas - خودرو بانک
Ranking MoonLake Immunotherapeutics among high performing stocks via toolsMarket Movers & Fast Entry Momentum Trade Alerts - Newser
MoonLake Immunotherapeutics stock prediction for this week2025 Top Gainers & Fast Moving Stock Trade Plans - Newser
Can a trend reversal in MoonLake Immunotherapeutics lead to recoveryPortfolio Risk Summary & Expert Verified Stock Movement Alerts - Newser
Will MoonLake Immunotherapeutics announce a stock splitWeekly Trend Recap & Weekly High Potential Stock Alerts - خودرو بانک
Can MoonLake Immunotherapeutics rally from current levels2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - Newser
When is the best time to exit MoonLake ImmunotherapeuticsStop Loss & Daily Stock Momentum Reports - Newser
MoonLake Immunotherapeutics stock daily chart insightsIndex Update & Technical Pattern Based Buy Signals - Newser
How hedge fund analytics apply to MoonLake Immunotherapeutics stockJuly 2025 Technicals & Real-Time Volume Triggers - Newser
Will MoonLake Immunotherapeutics price bounce be sustainable2025 Trade Ideas & Real-Time Stock Price Movement Reports - Newser
Using data models to predict MoonLake Immunotherapeutics stock movementWeekly Market Outlook & Smart Investment Allocation Tips - Newser
What Technical Tools Say About MoonLake Immunotherapeutics RecoveryQuarterly Profit Review & Precise Buy Zone Identification - beatles.ru
MoonLake Immunotherapeutics stock trend outlook and recovery pathWeekly Risk Summary & Free Real-Time Market Sentiment Alerts - Newser
What recovery options are there for MoonLake ImmunotherapeuticsTreasury Yields & Fast Entry High Yield Stock Tips - Newser
What Fibonacci levels say about MoonLake Immunotherapeutics reboundTrade Exit Report & Growth Focused Entry Reports - Newser
Visual analytics tools that track MoonLake Immunotherapeutics performanceWeekly Stock Analysis & Community Verified Trade Signals - Newser
Sentiment analysis tools applied to MoonLake ImmunotherapeuticsJuly 2025 EndofMonth & Trade Opportunity Analysis Reports - Newser
How sensitive is MoonLake Immunotherapeutics to inflation2025 Price Action Summary & Growth Focused Entry Reports - خودرو بانک
MoonLake Immunotherapeutics stock hits 52-week high at 58.3 USD By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics stock hits 52-week high at 58.3 USD - Investing.com
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moonlake Immunotherapeutics-Aktie (MLTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):